stars 1 stars 2 stars 3

Mobius Therapeutics™ is a commercial stage venture focused upon perioperative sterile injectables used in ophthalmic surgery. Its first product, Mitosol®, is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains an active sterile injectable product pipeline in varying stages of development. Please see full prescribing information at www.Mitosol.com and www.EyeAmphadase.com.

Mobius Therapeutics Questions

The Mobius Therapeutics annual revenue was $11 million in 2026.

Ed Timm is the Founder and Chief Executive Officer of Mobius Therapeutics.

8 people are employed at Mobius Therapeutics.

Mobius Therapeutics is based in St. Louis, Missouri.

The NAICS codes for Mobius Therapeutics are [32, 325, 3254, 32541].

The SIC codes for Mobius Therapeutics are [283, 28].

Top Mobius Therapeutics Employees

View Similar People
Learn More
How It Works
get free account
Get a Free Account
Sign up for a free account. No credit card required. Up to 5 free lookups.
search page
Search the #1 Contact Database
Get contact details of over 700M profiles across 60M companies – all with industry-leading accuracy. Sales and Recruiter users, try out our Email Finder Extension.
get contact page
Use our AI-Powered Email Finder
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.
G2 Leader Spring 2026 G2 Best Est ROI Mid Market Spring 2026 G2 Easiest Admin Mid Market Spring 2026 G2 Most Implementable Spring 2026 G2 Best Results Mid Market Spring 2026 G2 Lead Capture Mid Market Spring 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2025
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users